Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Sell
37
ROIV Quote, Financials, Valuation and Earnings
Last price:
$10.37
Seasonality move
:
12.09%
Day range:
$10.30 - $10.53
52-week range:
$9.96 - $13.06
Dividend yield:
0%
P/E ratio:
1.91x
P/S ratio:
47.26x
P/B ratio:
1.43x
Volume:
3.9M
Avg. volume:
6.1M
1-year change:
-1.52%
Market cap:
$7.4B
Revenue:
$124.8M
EPS (TTM):
-$0.15
Analysts' Opinion
-
Consensus RatingRoivant Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.00, Roivant Sciences has an estimated upside of 54.14% from its current price of $10.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $10.38.
Fair Value
-
According to the consensus of 7 analysts, Roivant Sciences has 54.14% upside to fair value with a price target of $16.00 per share.
ROIV vs. S&P 500
-
Over the past 5 trading days, Roivant Sciences has underperformed the S&P 500 by -2.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Roivant Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Roivant Sciences revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Roivant Sciences reported revenues of $9M.
Earnings Growth
-
Roivant Sciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Roivant Sciences reported earnings per share of $0.23.
Enterprise value:
2.6B
EV / Invested capital:
--
Price / LTM sales:
47.26x
EV / EBIT:
0.60x
EV / Revenue:
15.36x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.34x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
0.59x
Gross Profit (TTM):
$151.1M
Return On Assets:
-1.77%
Net Income Margin (TTM):
-68.71%
Return On Equity:
-1.94%
Return On Invested Capital:
-1.87%
Operating Margin:
-3042.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $43.1M | $68.2M | $169.7M | $15.6M | $9M | |
| Gross Profit | $33.7M | $59.4M | $151.1M | $15.4M | $8.8M | |
| Operating Income | -$1.1B | -$919M | -$1.3B | -$221M | -$274.4M | |
| EBITDA | -$1.3B | -$886M | $4.4B | -$215.6M | -$271.5M | |
| Diluted EPS | -$1.78 | $5.20 | -$0.15 | $6.03 | $0.23 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $2.3B | $1.6B | $6.8B | $5.4B | |
| Total Assets | -- | $2.8B | $2.2B | $7.3B | $5.8B | |
| Current Liabilities | -- | $160.7M | $244.3M | $244.9M | $141.5M | |
| Total Liabilities | -- | $529.6M | $775.8M | $728.1M | $256.4M | |
| Total Equity | -- | $2.3B | $1.4B | $6.6B | $5.5B | |
| Total Debt | -- | $204M | $412.8M | $449M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$811.8M | -$835.9M | -$775.3M | -$210.5M | -$207.3M | |
| Cash From Investing | -$163.5M | $5.3B | -$2.8B | $5.2B | $454.1M | |
| Cash From Financing | $290.2M | $662.3M | -$1.1B | $236.6M | -$273M | |
| Free Cash Flow | -$829.1M | -$838.6M | -$779.5M | -$210.8M | -$209.1M | |
ROIV
Sector
Market Cap
$7.4B
$36.5M
Price % of 52-Week High
79.51%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
12.75%
-0.9%
1-Year Price Total Return
-1.52%
-39.9%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$10.69
200-day SMA
Sell
Level
$11.31
Bollinger Bands (100)
Sell
Level
10.65 - 11.95
Chaikin Money Flow
Sell
Level
-22.7M
20-day SMA
Sell
Level
$10.62
Relative Strength Index (RSI14)
Sell
Level
42.16
ADX Line
Sell
Level
9.6
Williams %R
Buy
Level
-92.4107
50-day SMA
Sell
Level
$10.77
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
95.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.7538)
Buy
CA Score
(Annual)
Level (4.6749)
Sell
Beneish M-Score
(Annual)
Level (1.4701)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-16.6763)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Stock Forecast FAQ
In the current month, ROIV has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ROIV average analyst price target in the past 3 months is $16.00.
-
Where Will Roivant Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Roivant Sciences share price will rise to $16.00 per share over the next 12 months.
-
What Do Analysts Say About Roivant Sciences?
Analysts are divided on their view about Roivant Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Roivant Sciences is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Roivant Sciences's Price Target?
The price target for Roivant Sciences over the next 1-year time period is forecast to be $16.00 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ROIV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Roivant Sciences is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ROIV?
You can purchase shares of Roivant Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Roivant Sciences shares.
-
What Is The Roivant Sciences Share Price Today?
Roivant Sciences was last trading at $10.37 per share. This represents the most recent stock quote for Roivant Sciences. Yesterday, Roivant Sciences closed at $10.38 per share.
-
How To Buy Roivant Sciences Stock Online?
In order to purchase Roivant Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
